Efficacy News and Research

RSS

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Study: Stem cell transplant effective in halting degenerative disc disease of spine

Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans.

10 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Parents with bipolar disorder feel control by monitoring kids' moods

The majority of parents with bipolar disorder monitor their children's moods, which helps them feel in control of their child's wellbeing, show US study results.

7 Mar 2014

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Although there is widespread consensus among the scientific community that the composition of generic drugs is identical to that of brand name drugs, this is not the case among the public.

7 Mar 2014

New method of protecting women from transmission of HIV is safe

Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.

7 Mar 2014

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

A biomedical engineering researcher at the University of Arkansas will use a $416,897 grant from the National Cancer Institute to continue developing a new therapy for bladder cancer.

6 Mar 2014

Alkermes initiates pivotal clinical development program for treatment of MDD

Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

6 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Tetraphase Pharmaceuticals, Inc. today reported financial results for the quarter and full year ended December 31, 2013.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.

5 Mar 2014

Study highlights efficacy of TPF 50 to prevent skin sun damage and non-melanoma skin cancer

Journal of Drugs in Dermatology (JDD) today released a clinical study highlighting the efficacy of Triple Protection Factor Broad Spectrum Sunscreen, TPF 50, to prevent skin sun damage and Non-Melanoma Skin Cancer (NMSC).

5 Mar 2014

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.

5 Mar 2014

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.

5 Mar 2014

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center is among about a dozen centers nationally exploring the potential of a new drug that may offer relief to people with Parkinson's who have failed standard approaches to treating constipation.

5 Mar 2014

Efficacy News and Research

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

Antares Pharma announces launch of OTREXUP to Dermatologists

Study: Stem cell transplant effective in halting degenerative disc disease of spine

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

Parents with bipolar disorder feel control by monitoring kids' moods

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

New method of protecting women from transmission of HIV is safe

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Alkermes initiates pivotal clinical development program for treatment of MDD

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Study highlights efficacy of TPF 50 to prevent skin sun damage and non-melanoma skin cancer

Novel HIV prevention products for women demonstrate safety in clinical studies

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News